摘要
目的探讨唑来膦酸(Zoledronic Acid)对非小细胞肺癌骨转移的临床疗效。方法临床确诊的非小细胞肺癌骨转移患者52例,随机分组。氯甲膦酸二钠(固令)组26例:300mg静注,每日1次,连用5日,继而口服固令胶囊800mg,1日2次,连用15日。唑来膦酸组26例:4mg,静滴,一次使用。两组均以4周为1个治疗周期,4周后可重复使用。结果控制骨痛有效率,固令组61.54%,唑来膦酸组80.77%,治疗前后及组间比较均具有显著性差异(p<0.05);活动能力固令组有效率为42.30%,唑来膦酸组69.23%,组间比较差异显著(p<0.05),唑来膦酸组有效率中显效病例占有较高的比例;两组中血钙均明显下降,前后差异显著(p<0.05),组间未见显著性差异(p>0.05)。结论唑来膦酸能有效控制非小细胞肺癌骨转移性癌痛,改善活动能力,降低血钙含量,临床应用安全、可靠,患者耐受性好。
Objective To observe the acesodyne effect ,mobility and the change of serum calcium on skeletal metastases in non - small cell lung cancer. Methods 52 cases were randomized into Bonefos group（26 cases） ： 300 mg Qd ivdrip ,d1 -d5 ,800 mg bid po d6 -d20 ;Bonin group：60mg - 90mg ivdrip ; Zoledronic Acid group（26 cases） ：4mg iv drip. 4 weeks were as a course. Results The effective rate of acesodyne effect in Bonefos , Zoledronic Acid group were 61.54%, 80. 77% respectively , showing a significant difference （p 〈 0. 05 ）. The effective rates for mobility were 42. 30%, 69.23% in Bonefos , Zoledronic Acid group （p 〈 0.05 ） respectively. Acesodyne effect in Zoledrenic Acid group was better than that in Bonefos groups. The serum calcium decreased evidently after the treatment in both groups（p 〈 0.05）. There was no significent difference in both groups（p 〉 0.05 ）. Conclusion Zoledronic Acid has a significant curative effect on skeletal metastases in Non -Small Cell Lung Cancer.
出处
《现代医院》
2007年第3期23-25,共3页
Modern Hospitals
关键词
唑来膦酸
非小细胞肺癌
骨转移
Zoledronic Acid, non -small cell lung cancer, skeletal metastases
